Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase NA 1

Status

Completed 4Unknown 2

Sponsor Class

INDUSTRY 48OTHER 23NIH 6NETWORK 4

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 7Dermatologic 6CNS 4Sarcoma 2

Conditions

Melanoma 4Uveal Melanoma 2

Interventions

aldesleukin 69Cyclophosphamide 50fludarabine phosphate 36fludarabine 30Interleukin-2 27incomplete Freund's adjuvant 22Ipilimumab 20Biopsy 20Specimen Handling 19Magnetic Resonance Spectroscopy 19MART-1 Antigen 15CTLA-4 Antigen 15sargramostim 14Nivolumab 13Filgrastim 13montanide ISA 51 12Sorafenib 12Interferon-alpha 11pembrolizumab 10trametinib 9Temozolomide 9Bevacizumab 9dabrafenib 8temsirolimus 7Sirolimus 7Gene Expression Profiling 7tanespimycin 6Paclitaxel 6Dacarbazine 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
NIH × Dacarbazine × Dermatologic × Clear all
NCT01835145 2022-08-04

Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
47 enrolled 12 charts
Dermatologic

Uveal Melanoma

NCT01143402 2017-07-26

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

National Cancer Institute (NCI)

Phase 2 Completed
120 enrolled 8 charts
Dermatologic

Uveal Melanoma

NCT00016263 2014-01-06

Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma

National Cancer Institute (NCI)

Phase 3 Completed
Dermatologic

Melanoma

NCT00070343 2014-01-06

Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301

National Cancer Institute (NCI)

Phase NA Unknown
Dermatologic

Melanoma

NCT00072124 2013-06-19

Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma

National Cancer Institute (NCI)

Phase 3 Completed
Dermatologic

Melanoma

NCT00006200 2005-06-24

Thalidomide and Dacarbazine for Metastatic Melanoma

National Center for Research Resources (NCRR)

Phase 2 Unknown
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡